Radiotherapy (RT) is a common treatment for abdominal cancers like pancreatic tumors. Despite advancements in RT delivery, its effectiveness is hindered by the proximity of the radiosensitive intestine.
Category: Research
Develop strategies to ameliorate the course of Radiation-Induced Myocardial Fibrosis (RIMF)
Despite technological advancements in RT techniques, which enhance tumor targeting precision and minimize incidental cardiac doses, late cardiac toxicity remains a concern.
The role of STAT3 on pancreatic tumor radiosensitization
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor, with a 5-year survival rate of approximately 11%. While RT is used to mitigate tumor recurrence in advanced pancreatic cancer, it frequently leads to severe gastrointestinal side effects.
FLASH proton radiotherapy on normal tissues
The radiation dose that can be given to a tumor is limited by what the surrounding healthy tissues can tolerate. Studies over the past decade suggest that delivering radiation at ultra-high dose rates, exceeding 40 Gy/s and termed “FLASH” radiotherapy, reduces normal tissue damage compared with standard dose-rate delivery.
FLASH proton radiotherapy on tumors
Sparing normal tissue improves treatment only if tumor control is maintained. Across most of the tumor models we have tested, F-PRT is as effective as S-PRT at the same dose. Tumor growth inhibition is equivalent in pancreatic tumors, sarcomas (including an orthotopic intramuscular model), and melanoma. In orthotopic head and neck tumors, F-PRT did not compromise tumor control and improved survival.